Fig. 7

The effects of GPR39 KO in C57BL/6/Tar × CBA/Tar mice on seizure threshold in the MEST test (a) and on PTZ-induced epileptogenesis (b–d). a WT and GPR39 KO mice were subjected to the MEST test. Data are expressed as CS₅₀ (in mA) with upper 95% confidence limits. n = 20 in each group. P value was determined by the Student’s t-test (b) WT and GPR39 KO mice were injected i.p. once daily with TC-G 1008 (10 mg/kg) or VEH on every alternate day during weekdays. 30 min later, the mice were injected i.p. with PTZ (25 mg/kg). Immediately after each PTZ injection, the mice were subjected to an evaluation of behavioral seizures, which lasted 30 min. The total number of PTZ injections was 14. Data are expressed as means ± SEM of seizure severity after each injection (c) and the percentage of mice displaying consecutive stage 5 seizures after the last PTZ injection (d). One outlier was excluded in the WT TC-G 1008 group leading to n = 8 WT VEH, n = 6 WT TC-G 1008, n = 8 KO VEH, n = 7 KO TC-G 1008. p values were determined by three-way repeated measures ANOVA and Bonferroni’s multiple comparison test or Fisher’s exact test. *p < 0.05, **p < 0.01, ***p < 0.001